Beta subunit of human chorionic gonadotropin (beta-hCG), measured by immunoassay, is the major clinical marker in women with gestational trophoblastic neoplasia (GTN) —a disease spectrum that includes hydatidiform mole, nonmetastatic GTN, and metastatic GTN—and in about two thirds of men with testicular embryonal cancer or choriocarcinoma.